Skip Navigation

COVID-19 Update

We are vaccinating patients ages 16+. Learn more:

Vaccines | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker |  Email Alerts

 

A Reinvigorated Heart Transplant Program

A Reinvigorated Heart Transplant Program

Cardiothoracic surgeon Ahmet Kilic is sharply aware that he stands at the midpoint of a see-saw, one tilting downward.

New to Johns Hopkins, Kilic was hired both for his art and skill in transplanting hearts and for his expertise in the specifics of matching recipients with donors. If an organ is unavailable in a timely manner, the decision can be made to pursue surgical therapy in the form of a ventricular assist device (VAD) or other type of mechanical circulatory support system.

Kilic (pronounced “KIL-itch”) directs Johns Hopkins’ Heart Transplantation and Mechanical Circulatory Support Program. The goal: Protect patients’ overall tissue perfusion and restore a quality of life to patients facing chronic or end-stage heart failure.  

Still, he says, even with some two decades of worldwide research on VAD surgical implants, statistics on long-term survival fall short of perfect.

Donor hearts remain scarce, and adverse events from VADs, though fewer, dog the various mechanical circulatory support devices. The pumps can malfunction from clotting, with a subsequent risk of bleeding or stroke.

Moreover, fundamental questions persist: Why, in like patients in similar stages of cardiogenic shock, for example, does one patient achieve better than a one-year survival, while the other doesn’t? Do the devices themselves remodel still-normal, adjacent heart tissue? Do they sensitize patients’ immune systems? Can early insertion of a left ventricular assist device (LVAD) slow right-ventricle cardiomyopathy?

Kilic, however, is confident that, in the near future, surgical therapy can level the see-saw of outcomes for sicker patients and likely start its tilt in the other direction. LVAD design is steadily improving, for example. Also, Kilic says, there’s research on new materials—hybrids of biological and manmade agents to line the pumps—which seem patient-friendlier and discourage blood clots.

He ticks off other changes: “By using better criteria to select recipients, we have significantly changed patient responses to LVADs. And we’re more often introducing the pumps earlier, when people are less sick and better able to cope with the morbidity of surgery.”

That tactic goes hand-in-hand with an overall policy change in Johns Hopkins’ surgical heart failure therapy group. “We now see our advanced patients earlier as a team,” Kilic explains. “That means we do rounds together, bringing in the heart failure cardiologists, coordinators, nurses, intensivists and, of course, the surgeons to the bedside.” 

A last improvement comes as LVADs have become smaller, namely, using best practices to guide their insertion. While Kilic was program head at Ohio State’s Wexner Medical Center, for example, his lab fine-tuned placement of the HeartMate II, a “workhorse,” second-generation pump. It became the first one FDA-approved both as a lasting or “destination therapy” and as a temporary bridge to buy time for patients with refractory disease still on heart transplant lists.

Positioning the pump lower and securing it more tightly—part of the national PREVENT clinical trial—significantly discouraged in-pump clots.

Last fall, HeartMate III won approval as smaller, still, and even better-tolerated. “We’ve introduced this new pump to Johns Hopkins, along with the competitor HeartWare HVAD,” he says. Though each has its own niche, both pumps work by a new principle, Kilic says, where internal parts that might wear unduly are magnetized to repel each other.  

Because the HeartWare HVAD is the smallest yet, Kilic could introduce mini-sternotomies at Johns Hopkins. “The incision—shorter than the full sternotomy—lessens patients’ recovery time, with less discomfort,” Kilic notes.

Over the past several years, Johns Hopkins surgeons performed 10 to 25 heart transplants a year—around the average volume for a major center. Fewer LVAD surgeries happened last year, but Kilic notes, “We deal with the sickest of the sick patients, and we will always perform whatever the patient’s body tells us to do.”

“As we solve the shortcomings of device therapy, guided by our outcomes research, we can expect procedures to become more routine,” he adds. “So far, I like best care as opposed to most care, and that is absolutely what we strive for at Hopkins—it’s our bottom line.”

To discuss a case or refer a patient, call 410-955-7935.

back to top button